Literature DB >> 15814932

Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-D-glucose.

Setsu Sakamoto1, Kazunari Ishii, Kayo Hosaka, Tetsuya Mori, Masahiro Sasaki, Etsuro Mori.   

Abstract

BACKGROUND AND
PURPOSE: 2-[Fluorine 18]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has played an important role in detecting hypometabolic regions in the brains of patients with dementia. To our knowledge, the optimal imaging time for dementia has not been investigated. The aim of this study was to evaluate the sensitivity of the early scanning (ES) compared with late scanning (LS) for demonstrating decreased regional glucose metabolism in patients with Alzheimer disease (AD).
METHODS: Twenty patients with mild AD (mean age +/- standard deviation, 64.8 +/- 5.2 years) and 20 age- and sex-matched healthy volunteers (age, 65.9 +/- 4.5 years) were underwent FDG PET. Their cerebral glucose metabolic images were obtained on ES at 30-42 minutes and LS at 60-72 minutes after the administration of FDG 185-346 MBq. We compared regional cerebral metabolic images in a voxel-by-voxel analysis with statistical parametric mapping between patients with AD and control subjects and evaluated the difference in the hypometabolic regions between the two scans.
RESULTS: In the AD-to-healthy comparison, LS at the P < .001 level of significance showed more extensive and significant hypometabolic areas than did ES.
CONCLUSION: These results indicate that LS is superior to ES in detecting hypometabolic regions in patients with AD. For patients with AD, emission scanning soon after the administration of FDG is probably not advised.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814932      PMCID: PMC7977115     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  8 in total

1.  Cerebral glucose metabolic rates after 30 and 45 minute acquisitions: a comparative study.

Authors:  A Kumar; A Braun; M Schapiro; C Grady; R Carson; P Herscovitch
Journal:  J Nucl Med       Date:  1992-12       Impact factor: 10.057

2.  Glucose metabolism and rate constants in Alzheimer's disease examined with dynamic positron emission tomography scan.

Authors:  H Fukuyama; M Kameyama; K Harada; S Nishizawa; M Senda; T Mukai; Y Yonekura; K Torizuka
Journal:  Acta Neurol Scand       Date:  1989-10       Impact factor: 3.209

3.  Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease.

Authors:  K Ishii; M Sasaki; H Kitagaki; S Yamaji; S Sakamoto; K Matsuda; E Mori
Journal:  J Nucl Med       Date:  1997-06       Impact factor: 10.057

4.  Posterior cingulate cortex in Alzheimer's disease.

Authors:  S Minoshima; N L Foster; D E Kuhl
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

5.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.

Authors:  K Ishii; F Willoch; S Minoshima; A Drzezga; E P Ficaro; D J Cross; D E Kuhl; M Schwaiger
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

6.  Variation in FDG uptakes in different regions in normal human brain as a function of the time (30 and 60 minutes) after injection of FDG.

Authors:  Kazunari Ishii; Setsu Sakamoto; Kayo Hosaka; Tetsuya Mori; Masahiro Sasaki
Journal:  Ann Nucl Med       Date:  2002-06       Impact factor: 2.668

7.  Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method.

Authors:  K Schmidt; G Lucignani; R M Moresco; G Rizzo; M C Gilardi; C Messa; F Colombo; F Fazio; L Sokoloff
Journal:  J Cereb Blood Flow Metab       Date:  1992-09       Impact factor: 6.200

8.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.

Authors:  S Minoshima; K A Frey; R A Koeppe; N L Foster; D E Kuhl
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

  8 in total
  1 in total

1.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.